Outcome of Board Meeting

~)] nephroplus November 3, 2026 Ref: NEPHROPLUS/SE/95 To To BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Listing Centre Through: NEAPS Sub: Outcome of the Board Meeting held on November 3, 2026 Ref: Regulation 30, 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Ma’am, Pursuant to Regulations 30, 33 and other applicable provisions, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Board of Directors of the Company, at its meeting held today, i.e., Tuesday, November 3, 2026, inter alia, considered and approved the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026. The aforesaid Financial Results, along with the Limited Review Report issued by M/s. B S R and Co., Chartered Accountants (Firm Registration No. 128510W), Statutory Auditors of the Company, are enclosed herewith. The meeting of Board of Directors commenced at 04:00 p.m. IST and concluded at about 05:20 p.m. IST. A copy of this disclosure is also made available on the website of the Company www.nephroplus.com Yours faithfully, For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary and Head Legal Membership No.: F9895 Encl: a/a Nephrocare Health Services Limited (Global Co, pore,te Headquarters) (Formerly Nephrocare Health Services Pr1vate L11n1ted) s~ Floor. D Block, ,Labs Centre, Plot 18, Software Units Layout. Survey No 64, Madhapur, Hyderabad -500 081. Telangana. India ~ +91 40 4240 8039 B contactus@nephroplus com www nephroplus com CIN: L85100TG2009PLC066359 I GSTIN: 36AADCN1504A1Z8 I ISD GST: 36AADCN1504A2Z7 B S R and Co Salarpuria Knowledge City, Orwell B Wing, 6th Floor, Unit-3, Sy No. 83/1 Plot No. 02, Raidurg Chartered Accountants Hyderabad – 500 081, India Telephone + 91 407 182 2000 Fax + 91 407 182 2399 Limited Review Report on unaudited standalone financial results of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited) for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited) 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited) (hereinafter referred to as “the Company”) for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 (“the Statement”). Attention is drawn to the fact that the figures for the corresponding quarter ended 30 September 2025, as reported in the Statement have been approved by the Company’s Board of Directors, but have not been subjected to review. 2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it Principal Office: 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 2 B S R and Co Limited Review Report (Continued) Nephrocare Health Services Limited (formerly known as Nephrocare Health Services Private Limited) contains any material misstatement. For B S R and Co Chartered Accountants Firm’s Registration No.:128510W AMIT Digitally signed by KUMAR AMIT KUMAR BAJAJ Date: 2026.11.03 BAJAJ 17:45:57 +05'30' Amit Kumar Bajaj Partner Hyderabad Membership No.: 218685 03 November 2026 UDIN:26218685LXYQXU9974 Page 2 of 2 Nephrocare Health Services Limited (formerly Nephrocare Health Services Private Limited) CIN: L85100TG2009PLC066359 Regd.Office: 5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad• 500081 Email id: cs@nephroplus.com Ph. No. +91 40 4240 8039 Statement of Unaudited Standalone Financial Results for the quarter and half-year ended 30 September 2026 (f in Millions, except per share data) Quarter ended Half-year ended Year ended 30 September 2026 30June2026 30 September 2025 30 September 2026 30 September 2025 31 March 2026 Particulars Unaudited Unaudited Unaudited Unaudited Audited Audited (Refer Note 3) Income Revenue from operations 1,765.79 1,703.78 1,559.20 3,469.57 3,047.46 6,297.43 Other income 60.83 61.24 28.65 121.29 58.37 154.34 Total income 1,826.62 1,765.02 1,587.85 3,590.86 3,105.83 6,451.77 Expenses Cost of materials consumed 429.07 421.76 393.62 850.83 795.69 1,607.32 Employee benefits expense 345.90 308.02 304.00 653.92 596.62 1,210.86 Finance costs 6.74 4.85 410.47 11.59 445.25 497.61 Depreciation, amortisation and impairment expense 135.05 130.88 159.07 265.93 282.53 576.09 Healthcare professional fees 210.22 221.72 208.14 431.94 388.96 826.53 Hospital fees 201.75 179.00 171.61 380.75 335.58 685.33 Other expenses 328.78 331.86 247.11 659.86 498.39 1 085.72 Total expenses 1,657.51 1,598.09 1,894.02 3,254.82 3,343.02 6,489.46 Profit/ (loss) before tax 169.11 166.93 (306.17) 336.04 (237.19) (37.69) Tax expense Current tax 40.76 60.71 44.79 101.47 71.46 141.20 Deferred tax benefit (14.73) (19.41) (26.82) (34.14) (34.65) (98.29) Total tax expense 26.03 41.30 17.97 67.33 36.81 42.91 Profit/ (loss) for the period/year 143.08 125.63 (324.14) 268.71 (274.00) (80.60) Other comprehensive income Items that will not be reclassified to profit or loss -Remeasurement gain / (loss) on defined benefit plans (3.30) 0.17 0.65 (3.13) 1.31 0.68 -Income tax relating to items above 0.83 (0.04) (0.31) 0.79 (0.33) (0.17) Total other comprehensive income/ (loss) for the period/year (2.47) 0.13 0.34 (2.34) 0.98 [Showing first 8,000 characters — download PDF for full document]